08:43 ET Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain

Written By Ian DeVaan
Source: Longbridge

Medical 21, Inc. has received regulatory approval in Spain to initiate its first-in-human clinical trial for the MAVERICS Coronary Revascularization Study. This study will evaluate the company's next-generation regenerative small-diameter coronary bypass graft, designed to improve coronary artery bypass grafting (CABG) procedures. The MAVERICS graft aims to provide a durable alternative to harvested vessels, enhancing patient outcomes. This approval marks a significant milestone for Medical 21 in advancing its mission to transform coronary bypass surgery.

Ian DeVaan https://www.socialconstructmn.com
Previous

Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Next

Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain